The clinical relevance of sole loss of chromosome Y in myeloid neoplasms - Scorecard - MDSpire

The clinical relevance of sole loss of chromosome Y in myeloid neoplasms

  • By

  • Sandra Huber

  • Stephan Hutter

  • Manja Meggendorfer

  • Christian Pohlkamp

  • Torsten Haferlach

  • Isolde Summerer

  • May 9, 2026

  • 0 min

Share

Clinical Scorecard: The Importance of Isolated Loss of Chromosome Y in Myeloid Neoplasms

At a Glance

CategoryDetail
Condition
Key MechanismsAssociation with morphological features of MDS and potential immunosuppressive tumor microenvironment.
Target Population
Care Setting

Key Highlights

  • Clarify the association of LOY with superior survival rates compared to other karyotypes.

Guideline-Based Recommendations

Diagnosis

  • Add details on categorization based on WHO criteria.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Include specific treatment options for patients with high LOY clone sizes.

        Clinical Best Practices

        • examples

        Related Resources & Content

        Original Source(s)

        The clinical relevance of sole loss of chromosome Y in myeloid neoplasms

        • by Sandra Huber, Stephan Hutter, Manja Meggendorfer, Christian Pohlkamp, Torsten Haferlach, Isolde Summerer

        • May 9, 2026

        Related Content

        Refining CAR-NK Design

        Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

        • March 4, 2026

        • 2 min
        Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

        Roger Herschel Herzig: younger half of the dynamic duo which advanced leukaemia therapy and transplants: January 4, 1946 to July 18, 2020